CHESHIRE, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced key measures
to strengthen and broaden its executive leadership team in line with the
Company's expanding global mission to develop and commercialize
life-transforming therapies for patients with severe and rare disorders.
David Hallal is being promoted to the newly created position of Chief
Operating Officer and has been appointed to Alexion's Board of
Directors. Mr. Hallal had previously served as Executive Vice President
and Chief Commercial Officer, and will continue to lead all commercial
operations globally with responsibility for country operations in each
of Alexion's affiliates in EMEA, Japan, Australasia, and Latin America.
As Chief Operating Officer, Mr. Hallal will additionally now lead key
enterprise-wide initiatives and he will expand his role with external
stakeholders.
"David's focus and commitment to patient care and strong leadership
across our operations are an important component of the foundation for
Alexion's future growth," said Leonard Bell, M.D., Chief Executive
Officer of Alexion. "Additionally, David's increasing role to lead
enterprise-wide operations is vital as we expand globally to serve more
patients suffering with severe and life-threatening disorders in more
countries. As we continue to build Alexion, David's judgment and
experience will be an important additional voice on our Board of
Directors."
Clare Carmichael is being promoted to Executive Vice President and Chief
Human Resources Officer (CHRO) from her previous position of Senior Vice
President and CHRO. Ms. Carmichael will continue to lead and
significantly expand the Company's global talent initiatives including
talent management, talent acquisition, training and development, and
compensation and benefits.
"Clare has been a key leader in the ongoing transformation of Alexion
across each of our countries, regions, and corporate functions," said
Dr. Bell. "Clare has provided strong leadership to the transformation of
Alexion's talent and structure across the entire organization, including
senior management, which has been a critical component of our robust
growth. Under Clare's leadership, Alexion has grown from approximately
800 to more than 2,000 employees across an increasingly complex
organization now operating in nearly 50 countries. As we look to our
opportunity to serve more patients, Clare's increased responsibility
within the organization is vital as we continue attracting and retaining
the highest levels of talent required to serve patients across the globe
suffering with devastating and rare disorders."
John Moriarty, J.D. is being promoted to Executive Vice President and
General Counsel from his previous position of Senior Vice President and
General Counsel. Mr. Moriarty will continue to lead all of the Company's
legal, government affairs and corporate communications activities,
further expanding each of these functions to support the Company's
ongoing global growth.
"John has provided a strong vision of global leadership for the legal,
government affairs, and corporate communications functions at Alexion,
which have contributed significantly to our growth in the dynamic
environments in which we operate," said Dr. Bell. "Most noteworthy, John
has created a world-class legal team who are committed and proactive in
supporting the operations necessary to provide optimal care to patients
suffering with devastating disorders."
Additionally, the Company is pleased to announce that Edward Miller,
J.D. has joined Alexion in the newly created position of Senior Vice
President and Chief Compliance Officer. Mr. Miller will lead all
corporate compliance functions globally for Alexion.
"Ed has a very strong background domestically and internationally across
all areas of compliance. He has been a strong first-mover in the
industry to recognize the importance, and lead the development of
cultures and programs that promote compliance," said Dr. Bell. "As we
continue to grow worldwide to best serve patients, our commitment to
ethical business practices has never been greater, and Ed will continue
to build upon the strong compliance program Alexion has established over
the past several years."
"I am truly excited to be joining a company with such a strong focus on
patients and commitment to excellence," said Mr. Miller. "I hope to
build on that culture and enhance the already existing commitment to
compliance and ethics as we fulfill our mission of bringing innovative
treatments to patients with devastating conditions around the world."
All four executives will report directly to Dr. Bell.
The promotions of Mr. Hallal, Ms. Carmichael, and Mr. Moriarty, and the
addition of Mr. Miller, are designed to facilitate the further growth of
Alexion to serve more patients with severe and devastating disorders
around the world.
David L. Hallal
Mr. Hallal joined Alexion in 2006 to initiate the Company's U.S.
commercial operations, and has played the principal role in building
Alexion's successful global commercial platform to serve patients with
severe and life-threatening rare disorders. From his initial role where
he led the highly successful U.S. launch of the Company's first product,
Soliris® (eculizumab) in 2007, Mr. Hallal has progressively expanded his
responsibilities to Chief Commercial Officer. In addition to his
leadership of all commercial operations globally, Mr. Hallal has
responsibility for country operations in each of Alexion's affiliates in
EMEA, Japan, Australasia, Latin America. Mr. Hallal serves on all key
management decision-making committees. Mr. Hallal has more than 25 years
of experience in the biopharmaceutical industry, and prior to Alexion he
held commercial leadership positions at OSI Eyetech, Biogen Idec and
Amgen. Mr. Hallal holds a B.A. from the University of New Hampshire.
Clare Carmichael
Clare Carmichael joined Alexion in 2011 and has markedly impacted
Alexion's ability to grow our organization across an expanding and large
global platform at a rapid rate with the highest quality of staff. Under
Ms. Carmichael's leadership, Alexion has grown from approximately 800 to
more than 2,000 employees operating in nearly 50 countries. Ms.
Carmichael has 30 years of HR leadership experience in global
pharmaceutical and biotech organizations, and prior to Alexion, she held
leadership positions at Watson Pharmaceuticals, Schering-Plough
Corporation, Eyetech Pharmaceuticals, and Pharmacia Corporation. Ms.
Carmichael received a bachelor's degree from Rider University and
completed the University of Michigan Human Resources Executive Program.
John B. Moriarty, J.D.
John Moriarty joined Alexion in 2012 and has provided significant
leadership across his areas of responsibility including all global legal
matters as well as the Global Government Affairs and Corporate
Communications teams. Prior to joining Alexion, Mr. Moriarty was General
Counsel and Chief Legal Officer at Elan Corporation plc, and held
several legal leadership positions at Amgen, was an attorney in the
healthcare practice of a national law firm's Washington, D.C. and New
York offices, and was a healthcare fraud prosecutor in the U.S.
Attorney's Office and the Virginia Attorney General's Office. Mr.
Moriarty holds a J.D. from the University of Georgia School of Law and a
B.A. from the University of Virginia.
Edward Miller, J.D.
Mr. Miller has joined Alexion in the newly created position of Senior
Vice President and Chief Compliance Officer. Mr. Miller will lead all
compliance functions globally for Alexion. From 2000 to 2013, Mr. Miller
held numerous compliance and legal leadership positions at Boehringer
Ingelheim Pharmaceuticals/Boehringer Ingelheim GmbH, including Vice
President, Associate General Counsel, Global Litigation & Government
Investigations, Vice President/Acting Global Compliance Officer, Vice
President, Chief Compliance Officer and Head of Litigation, and Chief
Compliance Officer, Head of Litigation. At Boehringer Ingelheim, Mr.
Miller established the U.S. Compliance function and helped build the
Global Compliance function. Mr. Miller was previously a Senior Trial
Attorney in the U.S. Department of Justice, Civil Rights Division. Mr.
Miller obtained his undergraduate degree from Princeton University and
law degree from Rutgers University School of Law.
About Alexion
Alexion is a biopharmaceutical company focused on serving patients with
severe and rare disorders through the innovation, development and
commercialization of life-transforming therapeutic products. Alexion is
the global leader in complement inhibition and has developed and markets
Soliris® (eculizumab) as a treatment for patients with PNH and aHUS, two
debilitating, ultra-rare and life-threatening disorders caused by
chronic uncontrolled complement activation. Soliris is currently
approved in nearly 50 countries for the treatment of PNH, and in nearly
40 countries for the treatment of aHUS. Alexion is evaluating other
potential indications for Soliris in additional severe and ultra-rare
disorders beyond PNH and aHUS, and is developing other highly innovative
biotechnology product candidates across multiple therapeutic areas. This
press release and further information about Alexion can be found at www.alexionpharma.com.
[ALXN-G]
Alexion Pharmaceuticals
Media
Irving Adler, 203-271-8210
Executive
Director, Corporate Communications
or
Kim Diamond, 203-439-9600
Senior
Director, Corporate Communications
or
Investors
Elena
Ridloff, 203-699-7722
Executive Director, Investor Relations
Source: Alexion Pharmaceuticals, Inc.
News Provided by Acquire Media